Description
MAb Anti-6HIS-Eu cryptate Kinase Binding is an IgG2a raised against a polyhistidine tagged fusion protein labeled with Eu. It has been shown to react with 6HIS-tagged kinases.
This reagent is intended for use in the biochemical HTRF Kinase Binding platform.
HTRF assays offer many advantages over other technologies:
Homogeneous add-and-read format
No wash steps
Low background
Straightforward miniaturization from 96- or 384-well microplates to high density assay formats such as 384-well low volume and 1536-well plates
Stable signal, providing flexibility in time of readout or size of assays
Kd determination assay principal
The binding of the tracers is detected in a sandwich assay format using the Anti 6HIS antibody labeled with Europium Cryptate (donor), which binds to the 6HIS-tagged Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd) of the tracer to the 6HIS-tagged kinase.
Kd determination assay protocol
Saturation binding experiments on the three tracers (i.e. Staurosporine-Red, Dasatinib-Red, and Sunitinib-Red) can be run in 96- or 384-well plates (20 µL final volume). First, a dilution series of tracer ranging between 0 and 1 µM in the Kinase Binding Buffer is prepared in a 96-well non-binding plate. Next, 5 µL of Kinase Binding Buffer are dispensed into the final 96- or 384-well plate. Then 5 µL of 6HIS tagged-Kinase are added, followed by 5 µL of Anti-6HIS Eu-cryptate. Finally, 5 µL of the red tracer solution are added. The HTRF ratio is measured after 1 H of incubation.
IC50/Ki determination assay principle
Principle of HTRF® Kinase binding assay (IC50/Ki-determination). The binding of the tracers is detected in a sandwich assay format using the Anti-6HIS labeled with Europium Cryptate (donor), which binds to the tagged Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd ) of the tracer to the tagged kinase. When an inhibitor of the kinase is added, the tracer will be displaced and the HTRF signal will disappear, depending on the dose.
IC50/Ki determination assay protocol
Pharmacological evaluation of inhibitors of interest can be run in 96- or 384-well plates. First a dilution series ranging between 40 µM and 0.23 nM of inhibitor is prepared, and 5 µL of each concentration are dispensed into the plate. Next, 5 µL of tagged-Kinase are added, followed by 5 µL of anti-6HIS Eu-cryptate. Finally, 5 µL of tracer solution are added, prepared at 4x the final concentration. The HTRF ratio is measured after 1H of incubation. Analyses of the data give typical dose response curves ranging between 10 µM and 56 pM, enabling an evaluation of the IC50/Ki values for the inhibitor of interest.
Saturation Binding FGFR1-6HIS
A typical saturation binding experiment is performed using final tracer concentrations between 0 and 250 nM, and measuring total- and non-specific binding signals. Subtracting the non-specific from the total binding signal gives the specific signal, which can be analysed to give the Kd. Here an example is shown where the best tracer for inhibitor studies proved to be Staurosporine-Red, with a Kd of 22 nM on 5 nM FGFR1-6HIS.
Competitive Binding PDGFRb-6HIS
Dose response curves of various known kinase inhibitors (Staurosporine, Dasatinib, PP2, Imatinib, Tozasertib, Sunitinib, Gefitinib, and Sorafenib) were measured using Sunitinib-Red at its Kd (45 nM) on 5 nM PDGFRb-6HIS. Staurosporine, Dasatinib, Sunitinib, and Imatinib show showed high potencies, in good correlation with literature values.
